What DSIP Peptide Does in Sleep Research

DSIP peptide, short for delta sleep-inducing peptide, is a nonapeptide first identified in the 1970s from rabbit cerebral blood collected during sleep. It has not been approved by the FDA for any use, so what is known about it comes from a long and often contradictory research record rather than an approved drug label. This guide explains what DSIP is, how it has been classified and studied, why the findings have stayed so inconsistent, and how research material is handled and stored. It is written for research review, not as guidance for using DSIP on a person.

What DSIP Is and Where It Comes From

In simple terms, here is what researchers have studied DSIP for:

• Sleep patterns. Originally identified for a possible role in promoting deep, slow-wave sleep and reducing REM sleep in animal studies.
• Stress response. Studied as a possible stress-limiting factor that may blunt some hormonal stress markers.
• Withdrawal support. Examined in a small number of older clinical trials for easing opioid and alcohol withdrawal symptoms.
• Broader signaling. Found throughout the hypothalamus, pituitary, and other tissues alongside hormones such as ACTH and glucagon, suggesting a signaling role that may extend beyond sleep alone.

The technical details behind those effects:

• DSIP is a nonapeptide, a chain of nine amino acids, with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, first isolated in the 1970s by a Swiss research group from the blood of rabbits during sleep. Chemical databases also list it under the alternate name emideltide.
• In the founding 1977 study, researchers injected the synthesized peptide directly into the brains of 58 rabbits in a double-blind design and found it increased delta wave activity and sleep spindles on EEG recordings, while related fragments with altered amino acid sequences did not produce the same effect.
• Despite the name, no gene encoding DSIP has ever been confirmed in rabbits or any other species, and no dedicated DSIP receptor has been identified.
• The natural peptide is unstable outside the body, with a half-life of only about 15 minutes under laboratory conditions.
• DSIP appears in both free and protein-bound forms across the brain and several peripheral tissues, and researchers have proposed it travels bound to an unconfirmed carrier protein.

DSIP sits apart from most other research peptides covered on this site because, unlike growth hormone secretagogues or GLP-1 compounds, it has no confirmed receptor pathway behind its reported effects.

Is DSIP a Peptide, a Drug, or a Supplement

DSIP gets described loosely, so it helps to be precise about what kind of substance it actually is:

• A peptide, not a protein. A chain of nine amino acids makes DSIP a peptide. Proteins are typically much longer chains, so a nonapeptide like DSIP sits well below that size range.
• Not a vitamin, mineral, or supplement ingredient. DSIP has no history as a dietary supplement component and is not classified as one.
• An unapproved experimental compound, not a medication. DSIP has been given to participants in research trials, but a history of trial use does not make something an approved drug, a point covered further below.

How Researchers Think DSIP Might Work

Because no confirmed DSIP receptor exists, researchers have proposed several possible mechanisms rather than a single settled pathway:

• NMDA receptor involvement. Some studies suggest DSIP interacts with NMDA receptors, a receptor type involved broadly in learning, memory, and neuronal signaling.
• Adrenergic signaling. In rat studies, DSIP has been shown to influence an enzyme in the pineal gland by way of alpha-1 adrenergic receptors, part of the body’s noradrenaline signaling system.
• A glucocorticoid-linked pathway. Researchers have also compared DSIP to a protein called GILZ (glucocorticoid-induced leucine zipper), noting a structural resemblance that may connect DSIP to glucocorticoid hormone signaling and, by extension, stress and metabolism.
• GABA and glutamate signaling. A study on rat brain tissue found that DSIP altered the activity of GABA and glutamate receptors, two of the brain’s primary inhibitory and excitatory signaling systems, in the cortex, hippocampus, and cerebellum.

None of these proposed mechanisms has been confirmed as the primary way DSIP acts, and researchers studying the peptide have described the underlying biology as still unresolved even decades after its discovery.

What DSIP Research Has Actually Covered

Sleep is where DSIP research began and remains its most studied application, though the published literature covers a broader range of questions than the name suggests.

• Original findings. Early studies reported that DSIP promoted slow-wave sleep, the deep, restorative stage of sleep, and reduced REM sleep in animals.
• Later contradictions. Subsequent research has produced mixed results, with some studies finding no clear link between DSIP levels and sleep stages at all.
• Analog versus native peptide. Synthetic DSIP analogs, built to resist the rapid breakdown of the natural peptide, have shown more consistent sleep-related effects in some studies than the native nonapeptide itself.
• Human plasma patterns. Human studies have found that DSIP levels in blood plasma drop at the start of sleep regardless of what time of day sleep begins, though what that pattern means physiologically is still debated.

Beyond sleep, researchers have examined DSIP in a wider set of contexts:

• Opioid and alcohol withdrawal. In one older open-label clinical trial (a study where both researchers and patients knew who was receiving the real treatment), DSIP eased withdrawal symptoms in most of the opioid-dependent and alcohol-dependent patients who took part, though the small size and open-label design mean the finding has not been confirmed by larger, more rigorous studies.
• Stress hormone signaling. In a small double-blind trial in healthy men, intravenous DSIP temporarily lowered a stress hormone marker called ACTH-like immunoreactivity without changing cortisol levels, a narrow finding about a single biomarker rather than evidence of a stress-relieving effect.
• Anesthesia research. A separate trial in women undergoing surgery found that DSIP altered brain-wave and heart rate measurements during general anesthesia, with some findings pointing toward lighter rather than deeper anesthesia, the opposite of what a sedative would be expected to do.
• Pain, seizures, and stroke recovery. Separate animal studies have looked at DSIP’s effects on pain response, seizure activity, and, in more recent work, motor recovery after stroke in rats, generally in single studies that have not been widely repeated.

Why the Results Have Stayed Inconsistent

A 2006 review in the Journal of Neurochemistry summarized DSIP’s decades of research history as, in the reviewers’ own description, a still unresolved riddle. Several factors help explain why:

• No confirmed gene or receptor. Without an identified DSIP gene or receptor, researchers cannot fully explain how the peptide would produce any of its reported effects.
• A very short half-life. The native peptide breaks down within about 15 minutes, which pushes much of the research toward longer-lasting synthetic analogs and makes direct comparisons across studies difficult.
• Species differences. Reported effects vary across rabbits, rats, mice, cats, and humans, and a result in one species does not reliably predict the same result in another.
• Measurement challenges. Much of the human and animal data relies on antibody-based detection methods for DSIP-like material in blood or tissue, an approach that has introduced its own variability between labs and studies.
• A rigorous test came up thin. In a 1992 double-blind, placebo-controlled trial (neither researchers nor participants knew who got the real treatment, a stronger design than the open-label trials above) in 16 people with chronic insomnia, DSIP produced only modest, weak improvements in objective sleep measurements and no improvement in how rested participants said they felt, a result echoed by a separate crossover trial from the same era that found only slight improvement of limited clinical significance.

Because of these challenges, researchers working with DSIP have generally treated it as an open scientific question rather than a settled compound with a known mechanism.

What the Evidence Does and Does Not Show

Taken together, decades of DSIP research support a narrower set of conclusions than its long history might suggest:

• What the evidence supports. DSIP is a chemically well-defined nonapeptide that has been synthesized and given to human study participants, producing measurable but modest changes in some sleep, endocrine, and EEG measurements under tightly controlled conditions.
• What the evidence does not support. That DSIP acts as a genuine human sleep hormone, that a specific DSIP receptor exists, that it reliably reaches the brain by common administration routes, that it is an effective treatment for insomnia, stress, pain, seizures, or aging, or any conclusion about long-term safety, a standardized dose, or equivalence between different commercial DSIP preparations.

How Researchers Handle and Store DSIP

DSIP research material follows the same general handling conventions used across most peptide compounds on this site. It typically arrives as a freeze-dried powder that must be reconstituted, or mixed with a liquid, before use in a research setting, typically with bacteriostatic water, a sterile saline solution formulated to resist bacterial growth across repeated draws from the same vial.

• After mixing. Reconstituted material is stored refrigerated and used within the window described in the relevant study or supplier documentation, since DSIP, like most short peptides, breaks down faster once mixed into liquid form.
• Before mixing. Freeze-dried DSIP is more stable than the reconstituted form and should be kept according to the supplier’s storage instructions until it is prepared for research use.
• Getting the ratio right. Vial size and target concentration determine how much diluent to add, a calculation covered step by step in how to reconstitute peptides.

Why This Stays Research Use Only

DSIP carries its own set of open questions rather than the more established class-wide cautions seen with newer, heavily studied research compounds:

• No approved human use. DSIP has never been approved by the FDA, the European Medicines Agency, or the UK’s medicines regulator, and it does not have a large modern clinical trial program behind it.
• Long-term safety not established. Safety and possible side effects of extended DSIP use have not been established in controlled clinical research, since most of the human data comes from small, older studies rather than large randomized trials.

Research involving DSIP, including material such as the DSIP research vials available for laboratory use, should be treated as background for study design, not as a handling or dosing guide for any research material.

Research Use Only. This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.

Frequently Asked Questions

What is DSIP peptide?

DSIP, short for delta sleep-inducing peptide, is a nonapeptide first isolated from rabbit blood in the 1970s. It has been studied for a possible role in sleep and stress, though its exact mechanism has never been confirmed.

What does delta sleep mean?

Delta sleep is another name for slow-wave sleep, the deepest, most restorative stage of the sleep cycle, named for the slow delta brain waves seen on an EEG (a recording of brain electrical activity) during that stage. DSIP was named for its proposed link to this stage, not because the link has been proven.

Does DSIP actually improve sleep?

The evidence is mixed. Early animal studies reported effects on slow-wave sleep, but later research has produced inconsistent results, and no confirmed receptor explains how DSIP would produce such an effect.

Has DSIP been tested in humans?

Yes, in a handful of small, mostly older studies. The most rigorous of these, a 1992 double-blind, placebo-controlled trial in chronic insomnia patients, found only weak objective effects and no improvement in perceived rest, and no large modern human trial has been conducted since.

How was DSIP dosed in published research?

Study protocols vary, and none of them describe a self-administered routine. In the 1992 double-blind insomnia trial, clinical staff gave participants DSIP intravenously, at a dose of 25 nanomoles per kilogram of body weight, on three afternoons before overnight sleep monitoring in a laboratory. That is a controlled clinical research protocol, not a guide for using DSIP outside of one.

Is DSIP the same as melatonin?

No. Melatonin is a well-characterized hormone with an established receptor pathway. DSIP is a peptide with no confirmed receptor, and its relationship to sleep regulation remains an open research question.

Is DSIP legal?

DSIP is not approved by the FDA for any medical use and is sold for research use only. Current rules around its sale and use should always be checked directly rather than assumed.

Why has DSIP research stayed inconsistent for so long?

Researchers point to several factors: no confirmed gene or receptor, a very short half-life for the native peptide, differences across the species studied, and variability in the antibody-based methods used to measure it.

Sources

1. Schoenenberger GA, Maier PF, Tobler HJ, Monnier M (1977). A Naturally Occurring Delta-EEG Enhancing Nonapeptide in Rabbits. European Journal of Physiology.
2. Kovalzon VM, Strekalova TV (2006). Delta Sleep-Inducing Peptide (DSIP), a Still Unresolved Riddle. Journal of Neurochemistry.
3. Iyer KS, Marks GA, Kastin AJ, McCann SM (1988). Evidence for a Role of Delta Sleep-Inducing Peptide in Slow-Wave Sleep and Sleep-Related Growth Hormone Release in the Rat. Proceedings of the National Academy of Sciences.
4. Schneider-Helmert D, Schoenenberger GA (1981). The Influence of Synthetic DSIP (Delta-Sleep-Inducing-Peptide) on Disturbed Human Sleep. Cellular and Molecular Life Sciences.
5. Backmund M, Meyer K, Rothenhaeusler HB, Soyka M (1998). Opioid Detoxification With Delta Sleep-Inducing Peptide, Results of an Open Clinical Trial. Journal of Clinical Psychopharmacology.
6. Graf MV, Schoenenberger GA (1987). Delta Sleep-Inducing Peptide Modulates the Stimulation of Rat Pineal N-Acetyltransferase Activity by Involving the Alpha-1-Adrenergic Receptor. Journal of Neurochemistry.
7. Bes F, Hofman W, Schuur J, Van Boxtel C (1992). Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients, a Double-Blind Study. Neuropsychobiology.
8. Schoenenberger GA, Monnier M (1977). Characterization of a Delta-Electroencephalogram (Sleep)-Inducing Peptide. Proceedings of the National Academy of Sciences.
9. Grigor’ev VV, et al. (2006). Effects of Delta Sleep-Inducing Peptide on Pre- and Postsynaptic Glutamate and Postsynaptic GABA Receptors in Neurons of the Cortex, Hippocampus, and Cerebellum in Rats. Bulletin of Experimental Biology and Medicine.
10. Bjartell A, Ekman R, Bergquist S, Widerlov E (1989). Reduction of Immunoreactive ACTH in Plasma Following Intravenous Injection of Delta Sleep-Inducing Peptide in Man. Psychoneuroendocrinology.
11. Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D (1987). Study of Delta Sleep-Inducing Peptide Efficacy in Improving Sleep on Short-Term Administration to Chronic Insomniacs. International Journal of Clinical Pharmacology Research.
12. Pomfrett CJD, et al. (2009). Delta Sleep-Inducing Peptide Alters Bispectral Index, the Electroencephalogram and Heart Rate Variability When Used as an Adjunct to Isoflurane Anaesthesia. European Journal of Anaesthesiology.
13. Tukhovskaya EA, et al. (2021). Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats After Focal Stroke. Molecules.
14. National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 68816, Emideltide. PubChem.

Research compounds referenced above are stocked in the neuro and sleep category, alongside the rest of the shop.